Cargando…

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer

Docetaxel has been proved to provide survival benefit for advanced prostate cancer (PCa) patients. Resistance to docetaxel further reduces the survival of these patients. Herein, we performed a comprehensive bioinformatic analysis to identify differentially expressed genes (DEGs) between docetaxel s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Rui-ji, Li, Shu-ying-, Liu, Li-quan, Xu, Bin, Chen, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806863/ https://www.ncbi.nlm.nih.gov/pubmed/34077304 http://dx.doi.org/10.1080/21655979.2021.1936831

Ejemplares similares

Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells
por: Deng, Leihong, et al.
Publicado: (2019)

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer
por: Arichi, Naoko, et al.
Publicado: (2015)

Identification of biomarkers, pathways, and therapeutic targets for EGFR–TKI resistance in NSCLC
por: Zhu, Leilei, et al.
Publicado: (2023)

Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer
por: Singh, Santosh Kumar, et al.
Publicado: (2020)

Identification of biomarker microRNA-mRNA regulatory pairs for predicting the docetaxel resistance in prostate cancer
por: Tu, Jian, et al.
Publicado: (2019)

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer
por: Lin, Jian-Zhong, et al.
Publicado: (2017)

Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells
por: Qiu, Xiaofu, et al.
Publicado: (2019)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
por: Omoboyede, Victor, et al.
Publicado: (2023)

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance
por: Lima, Thiago S., et al.
Publicado: (2021)

Molecular mechanisms of docetaxel resistance in prostate cancer
por: Sekino, Yohei, et al.
Publicado: (2020)

Long noncoding RNA DANCR contributes to docetaxel resistance in prostate cancer through targeting the miR-34a-5p/JAG1 pathway
por: Ma, Yongliang, et al.
Publicado: (2019)

Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell
por: Liu, Chi-Ming, et al.
Publicado: (2017)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance
por: Bascetta, Lorenzo, et al.
Publicado: (2017)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
por: Sartor, A Oliver
Publicado: (2011)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
por: Huang, Houbao, et al.
Publicado: (2020)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
por: Karanika, Styliani, et al.
Publicado: (2015)

Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells
por: Ma, Yuanjun, et al.
Publicado: (2016)

Active Targeting of P-Selectin by Fucoidan Modulates the Molecular Profiling of Metastasis in Docetaxel-Resistant Prostate Cancer
por: Ho, Chang-Hsun, et al.
Publicado: (2022)

Microtubule-associated protein tau is associated with the resistance to docetaxel in prostate cancer cell lines
por: Yang, Jian, et al.
Publicado: (2017)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
por: Varnai, Reka, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Establishment and characterization of a docetaxel-resistant human prostate cancer cell line
por: Liu, Jian, et al.
Publicado: (2020)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
por: Kroon, Jan, et al.
Publicado: (2016)

Erratum to: Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells
por: Ma, Yuanjun, et al.
Publicado: (2016)

Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance
por: Zhang, Peng-Fei, et al.
Publicado: (2021)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011)

Overcoming docetaxel resistance in prostate cancer: a perspective review
por: Hwang, Clara
Publicado: (2012)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer
por: Sekino, Yohei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lvapmviqkcbmu74obg1tjc51fp